Drug name - Ibrance
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7208489 | PFIZER | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan, 2023
(3 months from now) | |
| US6936612 | PFIZER | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan, 2023
(3 months from now) | |
| USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(4 years from now) | |
| US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(11 years from now) | |
| CN105008357A | PFIZER | Solid State Form Of Selective Cdk4/6 Inhibitor |
Jul, 2020
(2 years ago) | |
| CN101906104B | PFIZER | 2-(Pyridin-2-Yl Amino)-Pyrido [2, 3-D] Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN101001857B | PFIZER | 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN102295643B | PFIZER | 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN102295643A | PFIZER | 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN101001857A | PFIZER | 2-(Pyridine-2-Yl Amido)-Pyridino[2,3-D]Pyrimidine-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN101906104A | PFIZER | 2-(Pyrid-2-Ylamino)-Pyridino[2,3-D] Pyrimidine-7-One |
Jan, 2023
(3 months from now) | |
| IN200401733P1 | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| IN218291B | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| EP1470124B1 | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| EP1470124A1 | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D]Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| EP2958916B1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| EP2958916A1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| EP3431475A1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| EP3431475B1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7456168 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan, 2023
(3 months from now) | |
| US11065250 | PFIZER | Solid dosage forms of palbociclib |
May, 2036
(13 years from now) | |
Drugs and Companies using PALBOCICLIB ingredient
Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 75MG | CAPSULE;ORAL | Prescription |
| 100MG | CAPSULE;ORAL | Prescription |
| 125MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.